Clinical Trials · Preventive Cardiology

ZEUS Trial: Ziltivekimab Fails to Cut MACE, Reigniting the Inflammation Debate

A clean biological signal met a flat clinical curve, and the residual-inflammation hypothesis now faces its most consequential stress test yet.

For physicians and physician-investors · August 2026

Ziltivekimab, an investigational interleukin-6 (IL-6) ligand inhibitor, did not reduce major adverse cardiovascular events (MACE) relative to placebo in the phase 3 ZEUS trial.

Topline results, released by drugmaker Novo Nordisk on July 31, 2026, showed a hazard ratio of 0.99 (95% CI 0.88–1.11) for the composite of cardiovascular death, nonfatal MI, or nonfatal stroke.

The result lands despite clear pharmacodynamic success, as ziltivekimab produced the expected reductions in free IL-6 and high-sensitivity C-reactive protein (hsCRP).

For an interventional and preventive cardiology audience already weighing whether to act on residual inflammatory risk, ZEUS forces a hard question: does biomarker modulation without outcome benefit undercut the inflammatory hypothesis of atherosclerosis, or simply indict this particular molecule in this particular population?

Trial Design and Topline Findings

ZEUS was a double-blind, placebo-controlled outcomes trial enrolling more than 6,300 adults with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and hsCRP levels of 2 mg/L or higher.

Participants received once-monthly subcutaneous ziltivekimab 15 mg or placebo on top of standard of care.

The fully human monoclonal antibody binds free IL-6, a proximal driver of the hepatic acute-phase response and a cytokine long implicated in plaque instability.

Despite achieving robust target engagement, the biological effect did not translate into a lower rate of the three-point MACE endpoint.

Overall adverse events, serious adverse events, and all-cause mortality were similar between arms.

Consistent with the known class effect of IL-6 pathway blockade, serious infections occurred more frequently with ziltivekimab than with placebo.

Two additional outcomes trials, HERMES in heart failure with preserved ejection fraction and ARTEMIS in post-MI patients, will proceed as planned, with readouts anticipated in the first half of 2027.

Full ZEUS results, including secondary and safety endpoints, are expected at a scientific meeting later in 2026.

Figure 1. Point estimates for MACE hazard ratios across major anti-inflammatory cardiovascular outcomes trials. Teal markers denote neutral trials; amber markers denote trials meeting their primary endpoint. Approximate values for illustration; consult primary sources for exact confidence intervals.

A Recurring Pattern: Target Engagement Without Outcome Benefit

ZEUS is not the first cardiovascular inflammation trial to separate biomarker response from clinical benefit.

CLEAR SYNERGY (OASIS 9), presented in late 2024, found that routine colchicine 0.5 mg daily did not reduce the composite of CV death, MI, stroke, or ischemia-driven revascularization when started within 72 hours of PCI for acute MI, despite a significantly larger CRP reduction in the colchicine arm.

That result stood in contrast to two earlier positive trials, COLCOT and LoDoCo2, which together underpinned the 2023 FDA approval of low-dose colchicine as the first anti-inflammatory agent indicated for cardiovascular risk reduction.

A parallel story played out with canakinumab, an interleukin-1β inhibitor that reduced MACE in the CANTOS trial among post-MI patients with elevated hsCRP, only for its manufacturer to abandon the cardiovascular indication after regulators requested additional safety and net-benefit data.

Across these programs, the common thread is a drug that reliably lowers hsCRP without a consistent, reproducible reduction in hard cardiovascular endpoints across settings and populations.

The 2025 American College of Cardiology scientific statement on inflammation and cardiovascular disease had characterized the evidence linking inflammation to ASCVD as clinically actionable and endorsed hsCRP testing alongside LDL-C in both primary and secondary prevention.

ZEUS does not overturn the prognostic value of hsCRP, but it does sharpen the distinction between hsCRP as a risk marker and IL-6 inhibition as a proven therapeutic strategy.

Why the Signal Might Be Missing

Several explanations are circulating among trialists and are worth weighing rather than treating the inflammatory hypothesis as disproven outright.

One possibility is population selection, since ASCVD-plus-CKD patients carry a mix of atherosclerotic and non-atherosclerotic risk that IL-6 blockade may not adequately address.

A second is timing, as chronic low-grade inflammation in stable outpatients may respond differently to cytokine blockade than the acute inflammatory surge following plaque rupture, a distinction also raised to explain the divergent CLEAR SYNERGY and LoDoCo2 results.

A third is competing risk from the infection signal, since any cardiovascular benefit from reduced plaque inflammation could be partially offset by increased infection-related morbidity in an immunosuppressed cohort.

A fourth is that free IL-6 and hsCRP reduction, while biologically reassuring, may not be adequate surrogates for the specific inflammatory pathways that drive plaque rupture and thrombosis.

Illustrative Case

A 68-year-old with prior MI, PCI to the LAD three years ago, and stage 3a CKD (eGFR 52) presents for a routine follow-up on high-intensity statin and a PCSK9 inhibitor, with LDL-C at goal but hsCRP persistently elevated at 4.2 mg/L on two occasions.

Before ZEUS, this profile might have prompted discussion of an investigational IL-6-targeted approach or reinforced consideration of low-dose colchicine for residual inflammatory risk.

After ZEUS, the practical takeaway is unchanged for colchicine, which retains its FDA indication and guideline standing for chronic, stable ASCVD outside the acute post-MI window studied in CLEAR SYNERGY, while ziltivekimab remains strictly investigational with no near-term path to clinical use in this population.

Agents Targeting the Inflammatory Pathway

Table 1. Selected anti-inflammatory agents studied for cardiovascular risk reduction

Agent	Target	Key CV Trial	CV Outcome	Regulatory Status (CV)
Colchicine (Lodoco, Colcrys, generic; Agepha Pharma/generics)	Microtubule/NLRP3 inflammasome	LoDoCo2, COLCOT; CLEAR SYNERGY neutral in acute post-MI PCI	Positive in chronic stable ASCVD; neutral in acute post-MI	FDA-approved (2023) for established ASCVD/risk reduction
Canakinumab (Ilaris; Novartis, NYSE: NVS)	IL-1β	CANTOS	Positive for MACE in post-MI patients with elevated hsCRP	No CV indication pursued; approved only for autoinflammatory conditions
Ziltivekimab (investigational; Novo Nordisk, NYSE: NVO)	Free IL-6 ligand	ZEUS	Neutral for MACE despite hsCRP/IL-6 reduction	Investigational; not approved for any indication

Financial and Pipeline Context

Novo Nordisk stated the ZEUS outcome will not alter its previously communicated 2026 adjusted operating profit outlook, though it will trigger a non-cash impairment charge in the third quarter of 2026.

As of early August 2026, analyst consensus on Novo Nordisk (NYSE: NVO) was rated a moderate "Buy," with a roughly $47 twelve-month consensus price target reported by aggregated sell-side coverage.

Given that GLP-1 receptor agonists dominate Novo Nordisk's revenue base, the ZEUS readout is a pipeline setback rather than a material threat to the company's near-term financial trajectory, and HERMES/ARTEMIS remain the more consequential ziltivekimab catalysts to watch into 2027.

Colchicine pricing varies substantially by formulation and pharmacy, with generic 0.6 mg colchicine available for roughly $15 to $30 for a 30-tablet supply through GoodRx coupons, while the branded cardiovascular-indicated formulation, Lodoco, carries substantially higher list pricing without a generic alternative currently available.

Stock prices, analyst ratings, and drug pricing shift frequently and should be independently verified before any clinical-financial correlation is drawn.

Clinical Trial Landscape at a Glance

Table 2. Anti-inflammatory cardiovascular outcomes trials: population and design

Trial	Population	N	Comparator	Primary Result
ZEUS	ASCVD + CKD + hsCRP ≥2 mg/L	>6,300	Ziltivekimab 15 mg monthly vs placebo	Neutral (HR 0.99)
CLEAR SYNERGY (OASIS 9)	Acute MI within 72h of PCI	7,062	Colchicine 0.5 mg daily vs placebo	Neutral (HR 0.99)
LoDoCo2	Chronic coronary disease	5,522	Colchicine 0.5 mg daily vs placebo	Positive
COLCOT	Recent MI (≤30 days)	4,745	Colchicine 0.5 mg daily vs placebo	Positive
CANTOS	Prior MI + hsCRP ≥2 mg/L	10,061	Canakinumab (3 doses) vs placebo	Positive at 150 mg dose

Bottom Line

Ziltivekimab achieved clean target engagement in ZEUS but produced no reduction in MACE among patients with ASCVD, CKD, and elevated hsCRP, joining CLEAR SYNERGY and the canakinumab CV-indication withdrawal as further evidence that lowering inflammatory biomarkers does not guarantee a clinical outcome benefit.

Colchicine's FDA-approved indication for chronic, stable ASCVD is unaffected by ZEUS, and hsCRP retains prognostic value, but the bar for a new anti-inflammatory agent to change practice just moved higher, not lower.

HERMES and ARTEMIS, reading out in 2027, will determine whether IL-6 inhibition has a future in heart failure or post-MI populations even after this ASCVD/CKD miss.

Physician education disclaimer: This article is intended for licensed healthcare professionals for educational purposes and does not constitute clinical practice guidance. Treatment decisions should be individualized and based on current FDA labeling, professional society guidelines, and the clinical judgment of the treating physician.

Financial disclaimer: This content is for informational and educational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. Stock prices, analyst ratings, and drug pricing are time-sensitive, approximate, and subject to change; verify current data independently before making any financial decision. The author is not a licensed financial advisor.

References

1. Novo Nordisk. Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation. Press release. July 31, 2026.
2. TCTMD. ZEUS Trial: Ziltivekimab Fails to Reduce MACE in ASCVD Patients. August 3, 2026.
3. TCTMD. Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows. October 29, 2024.
4. American College of Cardiology. New ACC Scientific Statement Details Role of Inflammation in CVD. September 29, 2025.
5. TCTMD. Hopes Fade for a CV Indication for Canakinumab: What's Next for the Inflammatory Hypothesis?
6. ClinicalTrials.gov. HERMES (NCT05636176) and ARTEMIS (NCT06118281) trial registrations.

Further Viewing

• Targeting Inflammation in Cardiovascular Disease: From Canakinumab to Colchicine — Cardiology Rounds lecture.
• Antiinflammatory Therapy and Cardiovascular Events — CANTOS trial overview.
• LoDoCo2 – Low-Dose Colchicine in Coronary Disease — ESC Congress 2020 discussion.

© 2026. All trial data current as of publication date; consult primary sources for full results when published.